Combining Disitamab Vedotin with Cisplatin for Cervical Cancer Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of Disitamab Vedotin combined with cisplatin as a neoadjuvant chemotherapy regimen for patients with locally advanced cervical cancer, specifically those with stage IB3 and IIA2 and positive HER2 expression. The primary objective is to assess the pathological complete response rate, while secondary objectives include evaluating safety, surgical outcomes, and overall survival. The study also aims to explore changes in tumor tissue protein expression and potential biomarkers for predicting treatment response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of cervical squamous cell carcinoma
* HER-2 positive

Exclusion Criteria:

* Cervical adenocarcinoma

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting

Study contacts

• Principal investigator: Kun Song — Qilu Hospital of Shandong University
• Study coordinator: Hualei Bu
• Email: buhualei@email.sdu.edu.cn
• Phone: 86-0531-82169269

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Enlonstobart with chemotherapy and radiotherapy for locally advanced cervical cancer

  This study tests whether adding Enlonstobart to standard chemotherapy and chemoradiotherapy helps patients with locally advanced cervical cancer by increasing response rates and monitoring safety.

  Recruiting at 2 sites Phase 4 Tianjin Medical University Cancer Institute and Hospital · Tianjin and 1 other locations · NCT07776821

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Immunotherapy Plus Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer

  This trial tests whether adding immunotherapy and chemotherapy to carbon ion radiotherapy can help women with locally advanced cervical cancer live longer without the cancer growing.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07702838

• Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer

  This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07646301

• Disitamab Vedotin Plus Radiotherapy for HER2-Expressing Upper Tract Urothelial Carcinoma After Surgery

  This study tests whether disitamab vedotin with radiotherapy can improve outcomes for people with HER2-expressing upper tract urothelial carcinoma after radical surgery who can’t receive cisplatin.

  Recruiting Phase 3 Peking University First Hospital · Beijing · NCT07498907

• Disitamab vedotin plus SOX versus SOX alone as adjuvant treatment for HER2-moderate/high stage III gastric cancer after surgery

  This trial will test whether adding disitamab vedotin to standard SOX chemotherapy helps people with HER2-moderate/high stage III gastric cancer after surgery stay cancer-free longer or live longer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07474324

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.